跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AS-183
首页
药物
AS-183
AS-183
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Through the MiR183 treatment of hyperlipidemia, fatty liver, type two diabetes and weight reduction method and drugs and their applications
申请人: KUNSHAN PENGJI KAIFENG BIOLOGICAL SCIENCE & TECH CO LTD
优先权: 2015
CN
Application of miR-183-5p inhibitor in preparation of medicine for promoting differentiation of neural stem cells
申请人: UNIV NANTONG
优先权: 2023
CN
HMGB1 recombinant vaccine for treating hepatic fibrosis and pharmaceutical application thereof
申请人: FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XIAN JIAOTONG UNIV
优先权: 2023
CN
MicroRNA related to stomach cancer thermochemotherapy sensitivity and application thereof
申请人: CANCER CT GUANGZHOU MEDICAL UNIV
优先权: 2022
CN
COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS
申请人: NANJING IMMUNOPHAGE BIOTECH CO LTD
优先权: 2021
EP
US
2 件公开
Human miR-183 gene cluster biological knock-down element, construction method and application thereof
申请人: 2ND PEOPLES HOSPITAL SHENZHEN
优先权: 2014
CN
GASTRIC CANCER RNA BIOMARKERS AND USES THEREOF
申请人: HOPE CITY
优先权: 2024
WO
Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
申请人: MIYAKAWA TOMOYA
优先权: 2004
CN
US
4 件公开
药物
反馈